Kiora and Théa Open Innovation Enter Partnership to Develop and Commercialize KIO-301
Read more
Contact MENU

News

Showing posts for — Category: Uncategorized

03.13.17

EyeGate Pharma Strengthens Scientific Advisory Board with Appointments of Daniel S. Durrie, M.D. and Randall J. Olson, M.D.

WALTHAM, Mass., March 13, 2017 -- EyeGate Pharmaceuticals, Inc. (NASDAQ: EYEG) (“EyeGate” or the “Company”), a clinical-stage specialty pharmaceutical company that focuses on developing and commercializing products for treating diseases...
Read more
02.06.17

EyeGate Pharmaceuticals Announces Executive Promotions

Sarah Romano named Interim Chief Financial Officer; Lisa Brandano and Carol Assang promoted to Vice President, Clinical Operations and Director, Clinical Operations, respectively WALTHAM, Mass., February 06, 2017 — EyeGate...
Read more
01.30.17

EyeGate Pharma Announces Positive Top-line Data from First-in-Human Pilot Trial of Ocular Bandage Gel in Corneal Epithelial Defects

Company Plans to Continue Development with Next Controlled Trial Q2 2017 WALTHAM, Mass., January 30, 2017 — EyeGate Pharmaceuticals, Inc. (NASDAQ: EYEG) (“EyeGate” or the “Company”), a specialty pharmaceutical company...
Read more
09.21.16

EyeGate Pharmaceuticals to Present at the 2016 Aegis Capital Conference

WALTHAM, Mass., Sept. 21, 2016 -- EyeGate Pharmaceuticals, Inc. (Nasdaq:EYEG), (“EyeGate” or the “Company”), a specialty pharmaceutical company that focuses on developing and commercializing products for treating diseases and disorders...
Read more
09.13.16

EyeGate Awarded $448,185 for second year of funding of Phase II SBIR Grant from U.S. Department of Defense

Funds to Advance Pre-clinical Development of CMHA-S Ocular Bandage Film WALTHAM, Mass., September 13, 2016 — EyeGate Pharmaceuticals, Inc. (NASDAQ: EYEG) (“EyeGate” or the “Company”), a specialty pharmaceutical company that...
Read more
05.13.16

Eyegate Pharmaceuticals Reports First Quarter 2016 Financial Results and Provides Business Update

WALTHAM, Mass., May 13, 2016 -- Eyegate Pharmaceuticals, Inc. (NASDAQ:EYEG) (“EyeGate” or the “Company”), a specialty pharmaceutical company that focuses on developing and commercializing therapeutics and drug delivery systems for...
Read more
05.06.16

EyeGate Pharma Appoints Dr. Brenda K. Mann as Vice President, Research and Development

WALTHAM, Mass., May 06, 2016 -- EyeGate Pharmaceuticals, Inc. (NASDAQ: EYEG) (“EyeGate” or the “Company”), a specialty pharmaceutical company that focuses on developing and commercializing therapeutics and drug delivery systems...
Read more
04.27.16

EyeGate Pharma Appoints Ryan R. Brenneman as Chief Financial Officer

WALTHAM, Mass., April 27, 2016 -- EyeGate Pharmaceuticals, Inc. (NASDAQ:EYEG) (“EyeGate” or the “Company”), a specialty pharmaceutical company that focuses on developing and commercializing therapeutics and drug delivery systems for...
Read more